Advertisement

Picture [iito] No Tracking 650x80px
Document › Details

Lava Therapeutics B.V.. (5/15/20). "Press Release: Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics". Utrecht.

Organisations Organisation Lava Therapeutics B.V.
  Organisation 2 Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
Products Product gamma-delta T cell engager
  Product 2 drug development
Index term Index term JnJ–Lava Therapeutics: bispecific antibodies, 202005– collab €na research + license agreem for bispecfic gamma-delta T-cell engagers Janssen Biotech
Person Person Hurly, Stephen (Lava Therapeutics 202005 CEO formerly 201307 CEO of Burrill Securities LLC)
     


Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation.

“We are excited to enter into this collaboration with Janssen, a global innovator and leader in the development of new medicines,” said Stephen Hurly, chief executive officer of Lava Therapeutics. “We strongly believe in the strength of our bispecific gamma-delta T cell engager platform and are committed to creating highly potent, target-specific therapeutics with increased durability and safety over current T cell-based approaches.”

Under the terms of the agreement, Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.


About Lava Therapeutics

Lava Therapeutics, B.V., is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach activates V?9Vd2 T cells upon binding to membrane-expressed tumor targets. Lava was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center, and is backed by Lupus Ventures, Biox Biosciences, Versant Ventures, Gilde Healthcare and MRL Ventures Fund. The company has established a highly experienced antibody research and development team located in Utrecht, the Netherlands (headquarters) and Philadelphia. For more information, please visit www.lavatherapeutics.com.


Contacts

Alicia Davis
THRUST Strategic Communications
alicia@thrustsc.com

   
Record changed: 2020-08-26

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Lava Therapeutics B.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top